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Many factors can interfere with glycemic control in patients with type 2 diabetes mellitus and this patient 
group has an increased risk of experiencing drug-related negative outcomes (DNO). The aim of this 
study was to identify the predictive factors of unsatisfactory glycemic control and DNO in this group 
of patients. A cross-sectional study was conducted collecting data from prescriptions and interviews 
with 100 patients of the Endocrinology Clinic of the Hospital Complex of Sorocaba, São Paulo, Brazil. 
Variables associated with unsatisfactory glycemic control were determined and the DNO associated 
with antidiabetic drugs identified. Age (<65 years) (OR=4.09), family history of diabetes (OR=3.24), 
use of combined therapy to treat diabetes (2-4 antidiabetic drugs) (OR=5.13) and presence of DNO 
(OR=5.92) were found to be predictive factors for poor patient glycemic control. DNO were observed 
in 49% of the patients and were caused predominantly by ineffectiveness in patients with poor glycemic 
control (p<0.05). There was no significant difference between groups (satisfactory and unsatisfactory 
glycemic control) for DNO caused by safety issues (p>0.05). Characterization of the profile of patients 
with uncontrolled diabetes and of aspects associated with drug treatment can contribute to the planning 
of interventions to improve patient care.
Uniterms: Type 2 Diabetes mellitus. Type 2 Diabetes mellitus/study/drugs use. Pharmaceutical care. 
Drug-related negative outcomes.
INTRODUCTION
Diabetes mellitus requires constant care and has 
reached high epidemiological levels. In 2013, the disease 
affected 11.9 million Brazilians over 18 years, ranking 
Brazil fourth in the world for number of people with 
diabetes (Almeida-Pititto, 2015). The disease affects 
17.1% of Brazilians aged 55-64 years and 22.1% of 
individuals over 65 years of age (Vigitel, 2012). Globally, 
prevalence among adults aged 20-79 was 8.3% (366.2 
million people) in 2011, a rate set to rise to an estimated 
9.9% by 2030, affecting approximately 552 million people 
(Whiting et al., 2011).
Due to the population’s growing longevity its 
accompanying demand for greater health care, diabetes 
represents a challenge for public health care (Trimeche et al., 
2013). Thus, strategies to reduce multifactorial risks and 
favor glycemic control are necessary (American Diabetes 
Association, 2014). The aim of treatment is to reduce 
morbidity and mortality related to the disease, where 
changes in lifestyle are recommended along with rational 
drug use and education for self-care (Correr et al., 2011).
Expert groups have produced several guidelines 
and the American Diabetes Association (ADA) guideline 
is generally accepted by the World Health Organization 
(WHO) and recommended by the Brazilian Diabetes 
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Association. These guidelines recommend glycated 
hemoglobin (HbA1c) levels lower than 7% for adults 
and up to 8% for the elderly for adequate glycemic 
control. HbA1c levels for the elderly take into account the 
increased risk of hypoglycemia, extensive comorbidities, 
and reduced life expectancy (Wallia, Molitch, 2014).
Glycemic control in type 2 diabetes mellitus 
prevents or reduces disease-related complications and 
is essential for controlling the intended glycemic targets 
(Saenz et al., 2005; Nathan et al., 2009; Duckworth et al., 
2009). However, lack of adherence to treatment (Donnan 
et al., 2002), cognitive dysfunctions (Grober et al., 2011), 
inappropriate eating habits, a sedentary lifestyle and 
overweight/obesity (Nathan et al., 2009), among other 
factors, have been shown to negatively influence the 
desired therapeutic goals. 
According to the literature, there is a high prevalence 
of drug-related problems (DRP) in diabetes mellitus 
patients (Von Rozendaal, Krass, 2009), mainly due to 
polypharmacy and high number of comorbidities (Zaman, 
Chai, 2013).
Pharmacotherapy follow-up is a clinical practice in 
which the pharmacist is responsible for the patient’s needs 
regarding the drug, through the detection, resolution, and 
prevention of drug-related negative outcomes (DNO). The 
Dader method for pharmacotherapy follow-up defines 
DRP as situations that hinder pharmacotherapy aims and 
may or may not result in DNO, which are considered 
inadequate for patient health and associated with the 
use or lack of use of drugs (Committee of Consensus, 
2007). This classification has been used in the literature 
by several authors (Zaman, Chai, 2013; Takahashi et al., 
2011; Gastelurrutia et al., 2011; Amariles et al., 2012).
The results of the present study can contribute to 
the creation of strategies that favor patient glycemic 
control by helping to identify the factors associated 
with unsatisfactory glycemic control of type 2 diabetes 
mellitus in patients as well as describing the drug treatment 
profile by identifying antidiabetic drug-related negative 
clinical outcomes. The aim of the study was to identify 
the predictive factors of unsatisfactory glycemic control 
and antidiabetic drug-related negative outcomes in type 2 
diabetes mellitus patients.
MATERIAL AND METHODS
Ethical aspects 
The study was approved by the Joint Ethics Research 
Committee of Sorocaba University - CEP-UNISO 
(Protocol 879,747).
Study design
A cross-sectional, analytical study was conducted.
Study population
All type 2 diabetes mellitus patients (n=197) 
scheduled for a medical appointment at the Endocrinology 
Clinic of the Hospital Complex of Sorocaba, São Paulo 
State, Brazil, between August 2013 and August 2014 were 
asked to participate in the study.
The patients were divided into 2 groups according 
to HbA1c test results: satisfactory and unsatisfactory 
glycemic control. Unsatisfactory glycemic control was 
defined as HbA1c ≥ 7% in adults and > 8% in elderly 
(American Diabetes Association, 2014; Brazilian Society 
of Diabetes, 2014).
Eligibility criteria
Individuals aged 18 or older with a positive 
diagnosis for type 2 diabetes mellitus for at least 6 months 
were included in the study. Individuals that did not have 
glycemic levels confirmed by the HbA1c test within the 4 
weeks leading up to the interview or that could not provide 
the necessary data for the study were excluded. 
Data collection
Pharmacists were invited by the physicians 
responsible for the Endocrinology Department (at the 
Conjunto Hospitalar de Sorocaba) to provide their 
services. After medical consultation, all the patients were 
taken by physicians to the pharmaceutical interview room. 
Patients that agreed to take part in this study formalized 
their acceptance by signing an informed consent form. 
Patients’ data were collected during the interview with 
the pharmacists, as well as from their respective medical 
prescriptions and medical records. During the interview, 
information about health problems (diagnosed or 
otherwise) and drugs used by patients was collected in 
order to check whether the drug treatment was appropriate 
in terms of indication, effectiveness and safety.
Sociodemographic  and c l in ica l  var iables 
(independent variables) associated with unsatisfactory 
patient glycemic control (dependent variable) were 
determined. Demographic variables (gender, age, housing, 
education, and average income) were obtained during the 
interview. Clinical variables (family history of diabetes, 
time since diagnosis, presence of complications due to 
diabetes, presence of comorbidities, obesity, use of insulin, 
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hypoglycemic crises, and polypharmacy) were obtained 
during the interview and also from medical records and 
prescriptions. Polypharmacy was defined as the use of 
three or more drugs (Noia et al., 2012).
The information allowing identification of the DNO 
was collected during the interview. Patients that had DNO 
were informed about the results and invited to participate 
in the pharmacotherapy follow-up program. 
The Dader method was used by the pharmacists to 
identify DRP and DNO according to the Third Consensus 
of Granada (Committee of Consensus, 2007). These were 
divided into three categories and six subcategories: 1) need 
(patient suffers from a health problem associated with not 
using the necessary drug or patient suffers from a health 
problem associated with using an unnecessary drug); 
2) effectiveness (patient suffers from a health problem 
associated with non-quantitative ineffectiveness of the 
drug and patient suffers from a health problem associated 
with quantitative ineffectiveness); and 3) safety (patient 
suffers from a health problem associated with non-
quantitative safety or patient suffers from a health problem 
associated with quantitative safety). 
Noncompliance with treatment was also established 
according to the Dader method, i.e., it may occur due to a 
problem of necessity (the patient does not use the drug or 
uses it inappropriately).
Standard product information from the Brazilian 
National Surveillance Agency and Drugdex® System 
(Klasco, 2013) was used in order to verify data regarding 
dosage, frequency, period of treatment, adverse effect, 
contraindications, and precaution with use and drug 
interactions. 
Drug interactions, and causality and severity of 
adverse effects were obtained by consensus among the 
pharmacists and, when necessary, the physicians attending 
the patients were also involved. Drug interactions were 
classified as severe (when threatening a patient’s life; 
it may or may not require medical intervention in order 
to prevent or minimize adverse effects), contraindicated 
(when it absolutely precludes the use of concomitant 
drugs) and moderate (when it may exacerbate patient’s 
health condition and/or requires changes in treatment) 
according to Klasco (2013). Drug interaction was 
considered when the result of this interaction was possibly 
associated with the clinical condition of the patient. Weak 
interactions were not considered. 
The Naranjo algorithm established the causality 
of the adverse effect as definite, probable, possible, or 
doubtful (Naranjo et al., 1981). Possible causes for adverse 
effects were considered when classified as definite (clinical 
situation that occurs in a reasonable period relative to the 
time drug has been administrated; it cannot be explained 
by the existing disease or another drug and/or chemical and 
is confirmed when the reaction disappears as the drug is 
suspended, but returns as drug is administrated again) and 
probable (as per the previously described criteria, but it is 
not necessary to reintroduce the drug). Regarding severity, 
the adverse effects were classified as lethal (contribute to 
patient’s death), severe (need to discontinue treatment and 
introduce specific treatment, leading to hospitalization or 
extended hospitalization), moderate (no need to interrupt 
and/or change treatment, but may need therapeutic 
changes and to extend hospitalization) or mild (no need to 
suspend pharmacotherapy or for specific treatment and/or 
antidotes) (Edwards, Aronson, 2000).
Statistical analysis
Bivariate analyses using the Chi-square test (χ2) or 
Fisher´s exact test was performed to test the influence of 
independent variables on the dependent variable. After 
this multiple logistic regression analyses, the stepwise 
procedure was performed in order to identify the risk 
indicators for unsatisfactory glycemic control. Only the 
independent variables with a p-value of less than 0.20 were 
tested in the regression analysis in order to eliminate those 
that would make little contribution to the model, where 
those with p≤0.05 remained in model after adjustments. 
The logistic regression models were adjusted estimating 
the Odds Ratios (OR), their 95% confidence intervals (CI), 
and significance levels. Statistical tests were performed 
using the SAS software program (SAS institute Inc. 2010, 
version 9.3, Cary, North-Carolina/USA) and Bioestat 5.3. 
The significance level was 5%. 
RESULTS
Of the 197 patients asked to participate in the study, 
103 agreed to take part but 3 (2.9%) were not eligible for 
the study because they did not have a glycated hemoglobin 
test. Sociodemographic and clinical variables are shown 
in Table I. The Chi-square test revealed a significant 
association between unsatisfactory glycemic control 
and age, family history for diabetes, obesity, insulin 
use, monotherapy or combination therapy for diabetes 
treatment, and DNO presence (p≤0.05). 
On the multiple logistic regression analysis, 
individuals aged under 65 (OR=4.09), with a family 
history for diabetes (OR=3.24), using combined therapy 
for diabetes treatment (OR=5.13), and having antidiabetic 
drug-related negative outcomes (OR=5.92), had a greater 
likelihood of unsatisfactory glycemic control (Table I).
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TABLE I - Sociodemographic and clinical variables associated with glycemic control in type 2 Diabetes mellitus patients 
Variables
Satisfactory 
(n=43)  
n (%)
Unsatisfactory 
(n=57) 
 n (%)
Bivariate analysis 
Crude OR  
(95%CI)
p-value
Multiple 
Analysis 
Adjusted OR 
(95%CI)
p-value
Gender
Female 26 (41.27) 37 (58.73) Ref
Male 17 (45.95) 20 (54.05) 0.83 (0.36-1.87) 0.6484
Age (years)
< 65 15 (29.41) 36 (70.59) 3.20 (1.40-7.31) 0.0051 4.09 (1.46-11.41) *0.0071
≥ 65 28 (57.14) 21 (42.86) ref ref
**Mean age 65.93 ± 10.66 59.63 ± 13.55
Housing
Resides alone  5 (29.41) 12 (70.59) 2.02 (0.65-6.26) 0.2142
Resides with family 38 (45.78) 45 (54.22) ref
Education (years)
≤ 4 5 (29.41) 12 (70.59) ref
> 4 38 (45.78) 45 (54.22) 0.49 (0.15-1.52) 0.2142
Monthly Income
≤ 1minimum wage 23 (43.40) 30 (56.60) ref
> 1 minimum wage 20 (42.55) 27 (57.45) 1.03 (0.46-2.28) 0.9323
Family history
No 15 (60.00) 10 (40.00) ref ref
Yes 28 (37.33) 47 (62.67) 2.56 (1.00-6.60) 0.0474 3.24 (0.96-10.96) *0.0059
Time since diagnosis (years)
≤ 10 17 (51.52) 16 (48.48) 0.59 (0.25-1.38) 0.2274
> 10 26 (38.81) 41 (61.19) ref
Diabetes complications
No 27 (47.37) 30 (52.63) 0.65 (0.29-1.47) 0.3097
Yes 16 (37.21) 27 (62.79) ref
Number of comorbidities 
0 - 2 24 (41.38) 34 (58.62) 1.17 (0.52-2.60) 0.7005
3 - 6 19 (45.24) 23 (54.76) ref
Obesity (BMI > 30 kg/m2)
No 38 (48.10) 41(51.90) 0.33 (0.11-1.00) 0.0457
Yes  5 (23.81) 16 (76.19) ref
Hypoglycemia 
No 15 (35.71) 27 (64.29) 1.68 (0.74-3.79) 0.2105
Yes 28 (48.28) 30 (51.72) ref
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Variables
Satisfactory 
(n=43)  
n (%)
Unsatisfactory 
(n=57) 
 n (%)
Bivariate analysis 
Crude OR  
(95%CI)
p-value
Multiple 
Analysis 
Adjusted OR 
(95%CI)
p-value
In use of insulin
No 22 (55.00) 18 (45.00) 0.44 (0.19-0.99) 0.0478
Yes 21 (35.00) 39 (65.00) ref
Drug for diabetes
Monotherapy 22 (73.33) 8 (36.67) ref ref
Association 21 (30.00) 49 (70.00) 4.38 (1.80-10.65) 0.0008 5.13 (1.69-15.51) *0.0038
Polypharmacy
No 3 (42.86) 4 (57.14) ref
Yes 40 (43.01) 53 (56.99) 0.99 (0.21-4.69) 0.4567
*Presence of DNO
No 33 (66.00) 17 (34.00) ref 
Yes 10 (20.00) 40 (80.00) 7.76 (3.13-19.23) 0.0001 5.92 (2.15-16.31) *0.0006
OR - odds ratio. CI – confidence interval. DNO – Antidiabetic drug-related negative outcomes. Category: “unsatisfactory” was 
the reference level of the dependent variable. * Statistically significant difference (Multiple Analysis, P ≤ 0.05). **Statistically 
significant difference (Student´s t-test, p≤0.05).
TABLE I - Sociodemographic and clinical variables associated with glycemic control in type 2 Diabetes mellitus patients (cont.)
No differences were observed between the groups 
for drugs used (p>0.05), which were metformin and NPH 
insulin, the most commonly prescribed. Monotherapy 
was more common in the satisfactory glycemic control 
group (p≤0.05). The combination of two antidiabetic 
agents predominated in the uncontrolled diabetes 
group (p≤0.05). For treatment regimens, the most 
prescribed for the satisfactory glycemic control group 
were monotherapy with metformin (p≤0.05) and the 
combination of metformin with NPH insulin (p>0.05). In 
the unsatisfactory glycemic control group, combinations 
of metformin and sulfonylureas and metformin with NPH 
insulin were the most prescribed (Table II).
Forty-nine patients (49.0%) had antidiabetic drug-
related negative outcomes, and 114 DNO were observed 
(average of 2.27 + 1.26 DNO/patient). No negative 
outcomes were found related to the need for drug use. 
A difference was detected regarding the quantitative 
ineffectiveness DNO due to non-compliance with daily 
dose (p≤0.05). The negative outcomes related to safety in 
the use of antidiabetic agents were mainly non-quantitative 
safety due to adverse effects and drug interactions 
(p>0.05). The number of ineffectiveness and safety DNO 
was higher in the uncontrolled diabetes group (p≤0.05) 
(Table III).
Table IV shows drug interactions possibly associated 
with DNO. Thirteen drug interactions associated with 
non-quantitative ineffectiveness were observed in the 
unsatisfactory glycemic control group, with a consequent 
risk of hyperglycemia. Drug interactions and precautions 
in use associated with non-quantitative and quantitative 
safety, respectively, were mainly associated with the 
risk of hypoglycemia. Five patients suffering from renal 
disease had quantitative unsafety DNO also related to the 
risk of hypoglycemia due to insulin use in the presence of 
the disease, which required dose adjustment. Overall, 22 
patients reported having presented hypoglycemic crises. 
Adverse effects were mainly related to the use 
of metformin where the most frequent effects included 
nausea, diarrhea, heartburn, and abdominal pain for both 
groups. These effects were categorized as definite and 
probable and having mild-to-moderate severity (Table V).
DISCUSSION
Diabetes is a high epidemiological chronic disease 
whose therapeutic goal is to maintain the glycemic control 
to prevent and/or postpone the related complications in 
order to provide benefits to the patients (Duckworth et al., 
2009; Holman et al., 2014). Therefore, knowing the factors 
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TABLE II - Frequency of drugs prescribed for type 2 Diabetes mellitus according to glycemic control
Satisfactory Unsatisfactory p-value
Glycated hemoglobin (%) mean ± SD mean ± SD
Adults 6.7 ± 0.47 8.9 ± 1.41 *0.0001
Elderly 7.2 ± 0.80 9.4 ± 0.83 *0.0001
Drugs (ATC) n (%) n (%)
Biguanide
Metformin (A10BA02) 32 (41.5) 47 (38.84) 0.8169
Sulfonylureas 
Glibenclamide (A10BB01) 2 (2.59) 3 (2.48) 1.0000
Gliclazide (A10BB09) 5 (6.49) 10 (8.27) 0.7853
Glimepiride (A10BB12) 5 (6.49) 3 (2.48) 0.2712
Alpha-glucosidase inhibitors
Acarbose (A10BH02) 1 (1.30) 0 (0) 0.4010
Gliptin
Vildagliptin (A10BH02) 1 (1.30) 4 (3.30) 0.6501
Insulins
Human NPH (A10AC01) 25 (32.47) 36 (29.75) 0.9901
Human Regular (R) (A10AB01) 6 (7.80) 18 (14.88) 0.1658
TOTAL 77 (100) 121 (100)
Monotherapy n (%) n (%)
Metformin (M) 14 (32.60) 5 (8.77) **0.0041
NPH Insulin (NPH) 8 (18.60) 3 (5.23) 0.0515
Subtotal 22 (51.2) 8 (14.0) **0.0002
Association of two antidiabetic drugs n (%) n (%)
M + Sulfonylureas (S) 3 (6.98) 12 (21.05) 0.0873
M + NPH 9 (20.93) 12 (21.05) 0.8157
M + Vildagliptin 0 4 (6.67) 0.1320
NPH + R Insulin 2 (4.65) 6 (10.53) 0.4604
NPH + S 1 (2.33) 0 (0) 0.4300
Subtotal 15 (34.9) 34 (59.6) **0.0244
Association of three antidiabetic drugs
M + NPH + R Insulin 4 (9.30) 11 (19.29) 0.2579
M + S + NPH 1 (2.33) 3 (5.26) 0.6325
M + Vildagliptin + Acarbose 1 (2.33) 0 (0) 0.4300
NPH + S + R Insulin 0 1 (1.75) 1.0000
Subtotal 6 (13.9) 15 (26.4) 0.2096
TOTAL 43 (100) 57 (100)
ATC - Anatomical Therapeutic Chemical. SD – standard deviation. *Statistically significant difference (Student´s t-test, P ≤ 0.05). 
**Statistically significant difference (Chi-square test, p≤0.05).
associated with poor glycemic control and antidiabetic drug-
related negative outcomes may contribute toward improving 
actions that favor glycemic control in these patients.
In the present study, unsatisfactory glycemic 
control in type 2 diabetes mellitus patients was associated 
with age group (<65 years), family history of diabetes, 
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presence of therapy associated with diabetes treatment, 
and antidiabetic drug-related negative outcomes.
Although age is considered a predictive factor in the 
prevalence of type 2 diabetes mellitus (Brazilian Society 
of Diabetes, 2014), the results of this study were similar 
for both adult and elderly groups and mirrored findings of 
Zaman and Fun (2013). Cramer (2004) observed that 73% 
of adult participants (mean age 50 years) had unsatisfactory 
glycemic control, similar to the rate found in the present 
study, in which 71% of adults had poor disease control.
According to the Brazilian Diabetes Association 
(2014), diabetes death rates (per 100 thousand persons) 
rise with age from 0.5 (0-18 years) to 213.4 (≥60 years) 
where these results could be partially explained by the 
prevalence of adults with uncontrolled disease. 
Some authors report that the following factors 
may limit glycemic control in type 2 diabetes mellitus 
patients: economic status, cognitive function impairment, 
comorbidities (Thompson et al., 2014), overweight/
obesity, disease diagnosed for long period (Ewenighi et 
al., 2013), lower adherence to drug treatment (Cramer, 
2004; Voorham et al., 2011; Ross, 2013), polypharmacy, 
adverse effects, use of injectable antidiabetic agents (Ross, 
2013; Thompson et al., 2014) and risk of hypoglycemia 
(Thompson et al., 2014). 
Among these factors, economic status, disease 
diagnosed for long period, obesity, comorbidities, 
hypoglycemic crises, polypharmacy, and the use of 
insulins as the main injectable antidiabetic agents were 
evaluated in the present study, but were not associated with 
the lack of control of diabetes in the population studied. 
The proportion of patients with an elevated number of 
comorbidities and hypoglycemic crises was very similar 
between the groups. Other variables associated with 
patients’ unsatisfactory glycemic control were use of 
antidiabetic agents in combined therapy and their negative 
drug outcomes.
Metformin and NPH insulin were the most commonly 
prescribed drugs, and monotherapy with metformin was 
more indicated for patients with satisfactory glycemic 
control (around 33% of prescriptions). In the present study, 
the patients that used two or more drugs for diabetes had 
a higher risk of not attaining the desirable glycemic levels 
for disease control. Adherence to treatment for type 2 
diabetes mellitus is one of the major obstacles to achieving 
the expected benefits of this pharmacotherapy (Donnan et 
al., 2002; Sunya-Lee et al., 2014).
Regarding treatment regimens, the most prescribed 
for the group of patients with satisfactory glycemic 
control was metformin combined with NPH insulin, while 
TABLE III - Antidiabetic drug-related negative outcomes according to glycemic control
DNO Categories/Subcategories Satisfactory n (%)
Unsatisfactory 
n (%) p-value
Inefficacy 
Non-quantitative inefficacy 
DRP: non-compliance with daily dose 0 (0) 16 (16.34) 0.1217
DRP: Drug Interaction 0 (0) 13 (13.26) 0.2088
Quantitative inefficacy
DRP: non-compliance with daily dose 0 (0) 33 (33.68) *0.0030
Subtotal 0 (0) 62 (63.3) *< 0.0001
Safety
Non-quantitative safety
DRP: Adverse effect 8 (50.00) 14 (14.28) 0.8102
DRP: Drug interaction 5 (31.25) 13 (13.26) 0.1135
Quantitative safety
DRP: Adverse effect 2 (12.50) 5 (5.10) 1.000
DRP: Precautions in use 1(6.25) 4 (4.08) 0.6712
Subtotal 16 (0) 36 (36.7) *< 0.0001
Total (n=114) 16 (100) 98 (100)
DNO - Antidiabetic drug-related negative outcomes. DRP – Drug-related problems. *Statistically significant difference (Fisher´s 
exact test, p≤0.05).
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in the unsatisfactory control group, the most common 
combinations were metformin and sulfonylureas and 
metformin with NPH insulin. The combination of two 
antidiabetic agents was predominant in this group, and 
there were a higher number of patients using up to three 
such agents. According to Brazilian Diabetes Association 
guidelines (2014), glycemic control must be achieved 
not only with the use of drugs, but also through lifestyle 
change, which includes improving eating patterns and 
physical activity. These factors were not investigated in the 
present study, but could help to explain the results found. 
Jarab et al. (2014) and Chung et al. (2014) underscored 
the importance of disease management as a predictive 
factor for its control.
According to Holman et al. (2009b), when glycemic 
control is not achieved with the use of oral antidiabetic 
agents, insulin may be added in order to intensify the 
therapeutic regimen since this - combination has been 
shown to be effective in reaching safe glycemic targets. 
The addition of insulin to the therapeutic regimen is 
necessary to maintain glycemic level stability in the long 
run (Valerón, Pablos-Velasco, 2013). 
Brazilian guidelines recommend the use of oral 
antidiabetic agents and insulin for type 2 diabetes mellitus 
TABLE IV - Characterization of drug interactions and precautions in use associated with drug-related outcomes according to 
glycemic control
Antidiabetic agents Other drugs Effects of interaction
Satisfactory 
n (%)
Unsatisfactory 
n (%) p-value
Non-quantitative ineffectiveness
R and/or NPH Levothyroxine Risk of hypoglycemia  0 (0) 8 (61.53) 1.000
R and/or NPH and/or metformin Atenolol or propranolol
Risk of 
hypoglycemia 0 (0) 5 (38.46) 1.000
Total 0 (0) 13 (100)
Non-quantitative safety
R and/or NPH
Losartan or 
acetylsalicylic 
acid
Risk of 
hypoglycemia 5 (100) 12 (92.30) 1.000
Metformin Digoxin
Risk of increased 
metformin plasma 
concentration
0 (0) 1 (7.70) 1.000
Total 5 (100) 13 (100)
Quantitative safety
Drug Clinical condition
Precaution in 
use (reasons)
R and/or NPH Renal failure or thyroid disease
Risk of 
hypoglycemia  1 (100)  4 (100) 1.000
R and/or NPH – Regular and/or NPH Insulin. No statistically significant difference (Fisher´s Exact test, p>0.05). 
TABLE V - Characterization of adverse drug reactions according to glycemic control
Drugs Adverse effect description Causality/Severity Satisfactory n (%)
Unsatisfactory 
n (%) p-value
Metformin Nausea, heartburn, diarrhea or abdominal pain
Definite or probable/mild 
or moderate 10 (100) 17 (89.47) 0.5320
R and/or NPH Hypoglycemia crisis Probable/moderate 0 2 (10.53) 0.4865
Total 10 (100) 19 (100)
R and/or NPH – Regular and/or NPH Insulin. No statistically significant difference (Fisher´s Exact test, p>0.05).
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treatment in monotherapy or combined therapy and in 
regimens established according to the disease history 
and patient’s clinical characteristics: HbA1c, fasting and 
postprandial glucose levels; current comorbidities; and 
reinforce that treatment must be individualized according 
to the patient’s characteristics (Brazilian Society of 
Diabetes, 2014).
Metformin was the most commonly used oral 
antidiabetic agent in monotherapy in patients with adequate 
glycemic control. This result corroborates the Brazilian and 
American guideline recommendations and the systematic 
review of Saenz et al. (2005), which reinforce the use of this 
drug as the first pharmacological option for type 2 diabetes 
mellitus monotherapy due to the superior results obtained 
in glycemic control for overweight or obese patients as well 
as the fact that it prevents vascular complications specific 
to diabetes and reduces mortality. 
Forty-nine percent of the patients in the present 
study had DNO. Zaman and Fun (2013) found that 90% of 
diabetic patients in the hospital had DRP. Gastelurrutia et 
al. (2011) observed DRP in 80% of patients suffering from 
heart failure seen in a medical clinic. These disparities 
may be attributed to the different populations studied and 
to the patient inclusion criteria, since in the present study 
patients were included regardless of specific criteria that 
required special pharmaceutical care. 
All patients were undergoing diabetic treatment and 
therefore had no negative outcomes related to untreated 
health problems. This is explained by the fact that the 
group of patients studied rigorously returned to the clinic 
every two to three months for a medical appointment. 
No problems were observed related to the unnecessary 
use of antidiabetic agents. The main problem observed 
in the unsatisfactory control group was the drug’s non-
quantitative ineffectiveness related to non-compliance 
with the frequency and/or the daily dose and to drug 
interactions that mainly occurred with the association of 
insulin with beta-blockers and levothyroxine, with the risk 
of reduced efficacy of these hypoglycemic agents.
In the present study, insulins were the main antidiabetic 
agents associated with drug interactions with the potential 
risk of generating negative outcomes due to ineffectiveness 
and safety. Drug interactions and precautions in use were 
mainly associated with the risk of hypoglycemic crisis. 
Metformin was associated with a higher number of adverse 
effects; one-third of adverse effects cases were due to the use 
of oral antidiabetic agents and insulin and more commonly 
hypoglycemia. Another study observed the main DRP for 
diabetes treatment: lack of knowledge regarding health 
problems, dosage problems, choice of drugs and drug 
interactions (Zaman, Fun, 2013).
The main problem related to the safety of antidiabetic 
agents in both groups was adverse effects, mainly due to 
the use of metformin associated with gastrointestinal 
symptoms. All of these effects were definite or probable 
and from mild to moderate, and no severe adverse effects 
were observed. Studies report that gastrointestinal 
discomfort is the most important metformin adverse effect 
(Valerón, Pablos-Velasco, 2013) and a strong relationship 
between polypharmacy and the presence of adverse effects 
was confirmed (Von Rozendaal, Krass, 2009; Gandhi et 
al., 2003; Braund et al., 2004; Onder et al., 2010). In the 
present study, most patients were in use of combined 
therapy.
Considering that this is a cross-sectional study, it 
was not possible to collect data that allowed the evaluation 
of pharmaceutical intervention effects. All patients were 
invited to participate in the pharmacotherapy follow-
up and around 15% accepted. Most of the patients 
demonstrated difficulty of displacement mainly due to old 
age and access to transport, since they live in cities near 
Sorocaba. Therefore, patients were oriented regarding 
pharmacotherapy and/or pharmacology during the 
interview and possibly, when they returned to the facility, 
while some of the interventions were made by contact from 
the doctors in the sector.
The pharmaceutical interview conducted using 
a systematic method of data collection for antidiabetic 
agents enabled the identification of their negative 
outcomes. These outcomes pose a threat to health, 
especially among adults with heart disease and/or diabetes 
mellitus (Al Hamid et al., 2014). Thus, the investigation 
and identification of DNOs may improve patient care 
regarding treatment.
CONCLUSIONS
In the present study, the factors associated with 
poor glycemic control in patients with type 2 diabetes 
mellitus were identified. Therefore, adults, individuals 
with a family history of diabetes, in use of two or more 
antidiabetic agents, and those exhibiting negative 
outcomes associated with the use of these drugs must be 
prioritized with regard to planning of interventions that 
favor disease control. The pharmaceutical interview also 
allowed identification of antidiabetic drug-related negative 
clinical outcomes and enabled the pharmacotherapy 
follow-up of some patients. Characterization of patient 
profile and aspects associated with drug treatment may 
contribute to the planning of interventions that improve 
patient care.
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